在HCC治疗中准自:利用CD147内部化途径
Meirui Qian1,2, Ziyu Wan1, Xue Liang1
1Department of Cell Biology, National Translational Science Center for Molecular Medicine, Fourth Military Medical University, Xi'an, 710032, China.
Cell communication and signaling : CCS
|December 3, 2024
概括
CD147内化触发保护性自,导致肝癌的化疗耐药性. 将化疗与自抑制剂相结合,有望提高治疗疗效.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- 化疗耐药性是肝癌治疗的一个重大挑战.
- 蛋白CD147与化学抵抗有关,但其确切的作用尚不清楚.
- 了解CD147的机制对于开发肝细胞癌 (HCC) 的有效疗法至关重要.
研究的目的:
- 研究CD147内化在诱导细胞保护性自中的作用.
- 阐明CD147对HCC的化疗耐药性的分子机制.
- 评估结合化疗与自抑制剂的治疗潜力.
主要方法:
- 对GEO和TCGA数据库进行生物信息分析,以确定关键分子.
- 在体外和体内研究使用过度表达/敲击系统来分析CD147内化和自.
- 免疫组织化学,免疫光学和质谱学用于研究临床样本中的CD147-G3BP1相互作用.
- 瘤异种移植小鼠模型,以评估自诱导和组合治疗的疗效.
主要成果:
- 在西斯普拉丁治疗后观察到CD147内部化和与G3BP1的相互作用,其次是 lysosomal 运输.
- CD147-G3BP1复合物抑制mTOR,促进自和增强肝瘤细胞中的化学抵抗.
- 在HCC患者中,增加的CD147内化与化疗复发和干细胞维护相关.
- 与西斯丁和氧化氨酸的联合治疗改善了小鼠的治疗疗效.
结论:
- CD147内部化和随后的CD147-G3BP1复合体的溶酶体转位通过mTOR抑制诱导细胞保护性自.
- 这种机制有助于降低HCC的化疗敏感性.
- 与化疗一起使用抑制剂向CD147介导的自,为HCC提供了潜在的治疗策略.
相关概念视频
Autophagy
4.2K
Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
4.2K
Delivery Pathways to the Lysosome
6.1K
Eukaryotic cells use different mechanisms to eliminate toxic waste obsolete and worn-out substances. Lysosomes play a pivotal role in this, and hence, these substances are carried to the lysosome from other parts of the cell and extracellular space through different pathways. The most elaborately studied pathways to the lysosome are the endocytic pathways.
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
6.1K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Autophagic Cell Death
3.4K
Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
3.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K


